Head-to-Head: which JAK inhibitor tames rheumatoid arthritis best?
NCT ID NCT07636057
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will compare two drugs, tofacitinib and upadacitinib, added to standard methotrexate treatment for rheumatoid arthritis. One hundred adults in Pakistan will take one of the two drugs daily for six months. Researchers will measure disease activity and side effects to see which drug works better and is safer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tofacitinib and upadacitinib (JAK inhibitors) added to methotrexate
What this could lead to
If this trial succeeds, it could show which JAK inhibitor works better for rheumatoid arthritis in the Pakistani population, helping doctors choose the most effective treatment.
What could go wrong
This is a small, early-stage study with only 100 participants, so results may not apply to everyone. Both drugs have known risks like infections, and the trial hasn't started yet.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••